However, studies on the regulation of ACLY to change the resistance of sorafenib in HCC cells are lacking, and clinical studies on the relationship between ACLY expression and sorafenib resistance in HCC are sparse. The gene discussed is ACLY; the disease is hepatocellular carcinoma.